Vaisala Group
6.3.2026 13:00:00 CET | Globenewswire | Press release
Vaisala Corporation: Managers’ Transactions – Vainio, Katriina
Vaisala Corporation: Managers’ Transactions – Vainio, Katriina
Vaisala Corporation
Managers’ Transactions
March 6, 2026, at 2:00 p.m. (EET)
Vaisala Corporation: Managers’ Transactions – Vainio, Katriina
____________________________________________
Person subject to the notification requirement
Name: Vainio, Katriina
Position: Other senior manager
Issuer: Vaisala Oyj
LEI: 743700RNDD7KU11HW873
Notification type: INITIAL NOTIFICATION
Reference number: 743700RNDD7KU11HW873_20260305144214_81
____________________________________________
Transaction date: 2026-03-05
Venue not applicable
Instrument type: SHARE
ISIN: FI0009900682
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 1003 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 1003 Volume weighted average price: 0.00 EUR
More information:
Niina Ala-Luopa, investor relations
+358 400 728 957, ir@vaisala.com
Distribution:
Nasdaq Helsinki
Key media
vaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With over 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.
www.vaisala.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Royal Philips24.8.2026 23:04:56 CEST | Press release
Philips prices EU green bond for EUR 650M
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Cosmos Health Inc.24.8.2026 21:40:00 CEST | Press release
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Kitron ASA24.8.2026 17:07:52 CEST | Press release
Kitron revises full-year 2026 outlook upwards
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom